Javier Velazquez-Moctezuma

Dr. Javier Velazquez-Moctezuma


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2012 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
BGBeatriz Gómez‐González
Beatriz Gómez‐González
EDEmilio Domínguez‐Salazar
Emilio Domínguez‐Salazar
GHGabriela Hurtado‐Alvarado
Gabriela Hurtado‐Alvarado
EEEnrique Esqueda‐Leon
Enrique Esqueda‐Leon
RSRafael Santana‐Miranda
Rafael Santana‐Miranda
JVJavier Velazquez-Moctezuma
Javier Velazquez-Moctezuma

1 January 2005 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
GVGonzalo Vázquez-Palacios
Gonzalo Vázquez-Palacios
HBHerlinda Bonilla-Jaime
Herlinda Bonilla-Jaime
JVJavier Velazquez-Moctezuma
Javier Velazquez-Moctezuma

1 January 2015 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
SONIA LEON-CABRERASONIA LEON-CABRERA
SONIA LEON-CABRERA
YAYoaly Arana-Lechuga
Yoaly Arana-Lechuga
EEEnrique Esqueda-León
Enrique Esqueda-León
GTGuadalupe Terán-Pérez
Guadalupe Terán-Pérez
AGAntonio Gonzalez-Chavez
Antonio Gonzalez-Chavez
JVJavier Velazquez-Moctezuma
Javier Velazquez-Moctezuma
Obstructive sleep apnea (OSA) has been related to elevation of inflammatory cytokines and development of insulin resistance in morbidly obese (MO) subjects. However, it is still unclear whether the systemic concentration of anti‐inflammatory mediators is also affected in MO subjects directly related to the severity of OSA and level of insulin resistance. Normal weight and MO subjects were subjected to overnight polysomnography in order to establish the severity of OSA, according to the apnea‐hypopnea index (AHI). Blood samples were obtained for estimation of total cholesterol and triglycerides, insulin, glucose, insulin resistance, tumor necrosis factor alpha (TNF‐α), interleukin 12 (IL12), and interleukin 10 (IL‐10). Serum levels of IL‐10 were significantly lower in MO subjects with OSA than in MO and control individuals without OSA. Besides being inversely associated with serum TNF‐α and IL‐12, decreased IL‐10 levels were significantly related to increased AHI, hyperinsulinemia, and insulin resistance. Serum IL‐10 is significantly reduced in morbidly obese subjects with severe OSA while also showing a clear relationship with a state of hyperinsulinemia and insulin resistance probably regardless of obesity in the present sample. It may be of potential clinical interest to identify the stimulatory mechanisms of IL‐10 in obese individuals with OSA.

Verified
Journal Article
Open access
PDF file
JAJesús Argueta
Jesús Argueta
HSHector Solis-Chagoyan
Hector Solis-Chagoyan
REROSA ESTRADA-REYES
ROSA ESTRADA-REYES
LCLuis Alejandro Constantino-Jonapa
Luis Alejandro Constantino-Jonapa
JSJulián Oikawa Sala
Julián Oikawa Sala
GBGloria Benítez-King
Gloria Benítez-King
Melatonin (MEL) is a pleiotropic indolamine that reaches multiple intracellular targets. Among these, MEL binds to calmodulin (CaM) with high affinity. In presence of Ca2+, CaM binds to CaM-dependent kinase II (CaMKII). The Ca2+-CaM/CaMKII pathway regulates a myriad of brain functions in different cellular compartments. Evidence showing the regulation of this cellular pathway by MEL is scarce. Thus, our main objective was to study the interaction of MEL with CaM and its effects on CaMKII activity in two microenvironments (aqueous and lipidic) naturally occurring within the cell. In addition, colocalization of MEL with CaM in vivo was explored in mice brain hippocampus. In vitro CaM-MEL interaction and the structural conformations of CaM in the presence of this indoleamine were assessed through electrophoretic mobility and isoelectric point. The functional consequence of this interaction was evaluated by measuring CaMKII activity. Ca2+-CaM-MEL increased the activity of CaMKII in aqueous buffer but reduced the kinase activity in lipid buffer. Importantly, MEL colocalizes in vivo with Ca2+-CaM in the hippocampus. Our evidence suggests that MEL regulates the key cellular Ca2+-CaM/CaMKII pathway and might explain why physiological MEL concentrations reduce CaMKII activity in some experimental conditions, while in others it drives biological processes through activation of this kinase.

1 April 2016 in Sleep Medicine
Verified
Journal Article
Closed access
OSO. Sánchez-Escandón
O. Sánchez-Escandón
YAY. Arana-Lechuga
Y. Arana-Lechuga
GTG. Terán-Pérez
G. Terán-Pérez
Ángel Alberto Ruiz-ChowÁngel Alberto Ruiz-Chow
Ángel Alberto Ruiz-Chow
RGR. González-Robles
R. González-Robles
JVJavier Velazquez-Moctezuma
Javier Velazquez-Moctezuma

9 January 2002 in Behavioural Brain Research
Verified
Journal Article
Closed access
AFA Ferreira-Nuño
A Ferreira-Nuño
DOD.H Overstreet
D.H Overstreet
AMA Morales-Otal
A Morales-Otal
JVJavier Velazquez-Moctezuma
Javier Velazquez-Moctezuma